The FDA has approved Fiasp (insulin aspart injection) 100 units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with types 1 and 2 diabetes.

Indications: Fiasp is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

Dosage and administration:

• Individualize and adjust the dosage of Fiasp based on route of administration, individual’s metabolic needs, blood glucose monitoring results, and glycemic control goal.
• Subcutaneous injection: Inject at the start of a meal or within 20 minutes after starting a meal into the abdomen, upper arm, or thigh.
• Intravenous infusion: Administer only under medical supervision after diluting to concentrations from 0. 5 to 1 unit/mL insulin aspart in infusion systems using polypropylene infusion bags.

Efficacy and safety: Approval is based on results from a trial showing that participants taking Fiasp reduced A1C levels.

Side effects/risks: The most common adverse reactions are hypoglycemia, allergic reactions, hypersensitivity, injection site reactions, lipodystrophy, and weight gain.